Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies, An Issue of Clinics in Liver Disease
Series: The Clinics: Internal Medicine;
- Publisher's listprice EUR 91.99
-
38 152 Ft (36 336 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 13% (cc. 4 960 Ft off)
- Discounted price 33 193 Ft (31 612 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
38 152 Ft
Availability
Not yet published.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher Elsevier Health Sciences
- Date of Publication 28 May 2026
- ISBN 9780443413537
- Binding Hardback
- No. of pages pages
- Language English 700
Categories
Long description:
In this issue of Clinics in Liver Disease, guest editor Dr. Zobair M. Younossi brings his considerable expertise to the topic of MASH/NASH Fatty Liver. With an estimated 115 million people worldwide affected by MASH, the disease burden casts a wide net: many have other comorbidities, like diabetes, that make diagnosis and treatment critical. MASH-related liver cancer has increased 20% since 1990, and MASH is becoming a leading cause of liver transplants in adults, reflecting its significant impact on liver health. This issue provides state-of-the-art clinical reviews on MASH and NASH and also shines a light on the disease burden across the globe.
- Contains 19 relevant, practice-oriented topics including association of MASH with metabolic-related diseases (diabetes, pre-diabetes, and obesity); algorithms for risk stratification in patients with MASH; management of MASLD: lifestyle modification; currently approved and future regimens for MASH; pediatric MASH; and more
- Provides in-depth clinical reviews on MASH/NASH fatty liver, offering actionable insights for clinical practice
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews
